Johnson & Johnson has retained its position as the world’s most valuable pharma brand, with a brand value of US$10.8 billion. Aside from successfully entering the COVID-19 vaccine race - with nearly nine million Americans vaccinated with it as of May 2021 Johnson & Johnson continues to showcase its position as the world’s largest healthcare company, celebrating several significant achievements over the last year, and ensuring that its approvals and pipeline of approvals remain on track.

2020 was a record year for research and development for Johnson & Johnson, with the brand investing US$12.2 billion, up from US$800 million in 2019. This, paired with over seven billion dollars’ worth of acquisitions, has put the brand in a strong position to continue to grow in the coming year and beyond the pandemic.

Despite recording a marginal 1% drop in brand value, Johnson & Johnson retains a healthy lead over second-placed Roche, with a brand value of US$7.7 billion. In addition to measuring overall brand value, Brand Finance also determines the relative strength of brands through a balanced scorecard of metrics evaluating marketing investment, stakeholder equity, and business performance. Alongside revenue forecasts, brand strength is a crucial driver of brand value. According to these criteria, Roche is the world’s strongest pharma brand with a Brand Strength Index (BSI) score of 74.2 out of 100 and corresponding AA brand strength rating.